Subtopic Deep Dive
PRKAR1A Mutations in Carney Complex
Research Guide
What is PRKAR1A Mutations in Carney Complex?
PRKAR1A mutations cause Carney complex, an autosomal dominant syndrome characterized by cardiac myxomas, endocrine tumors, and pigmented skin lesions through disrupted protein kinase A signaling.
Inactivating mutations in PRKAR1A, encoding the type I-α regulatory subunit of protein kinase A, lead to Carney complex with frequent cardiac myxomas. Kirschner et al. (2000) identified these mutations in patients, amassing 1130 citations. Stratakis et al. (2001) outlined diagnostic criteria, cited 771 times, emphasizing genotype-phenotype correlations.
Why It Matters
PRKAR1A mutations enable genetic screening for familial Carney complex, preventing cardiac myxoma complications like embolism (Stratakis et al., 2001). Insights into PKA pathway disruptions guide targeted therapies for myxomas and endocrine overactivity (Bossis and Stratakis, 2004). Mouse models validate neoplasia in cAMP-responsive tissues, supporting preclinical testing (Kirschner et al., 2005). Clinical updates refine evaluation protocols, improving outcomes in heritable cardiac tumors (Correa et al., 2015).
Key Research Challenges
Mutation Spectrum Variability
PRKAR1A mutations vary widely, including point mutations and large deletions, complicating genetic diagnosis. Horvath et al. (2010) cataloged polymorphisms and inactivating variants across cohorts. Phenotype-genotype discordance hinders predictive screening (Stratakis et al., 2001).
Cardiac Myxoma Recurrence
Recurrent myxomas post-resection pose management challenges in Carney complex patients. Correa et al. (2015) noted high cardiac involvement rates. Surgical and surveillance strategies lack standardization despite genetic insights (Kirschner et al., 2000).
PKA Signaling Modeling
Disrupted PKA holoenzyme regulation from PRKAR1A loss requires advanced pathway models. Bossis and Stratakis (2004) detailed RIα functions in cAMP response. Mouse models show tissue-specific neoplasia but translation to humans remains limited (Kirschner et al., 2005).
Essential Papers
Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex
Lawrence S. Kirschner, J. Aidan Carney, Svetlana Pack et al. · 2000 · Nature Genetics · 1.1K citations
Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient Evaluation
Constantine A. Stratakis, Lawrence S. Kirschner, J. Aidan Carney · 2001 · The Journal of Clinical Endocrinology & Metabolism · 771 citations
Carney complex is a multiple neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors, as well as a variety of pigmented lesions of the skin and mucosae. Carney complex is inhe...
Carney complex: an update
Ricardo Correa, Calvin Ke, Constantine A. Stratakis · 2015 · European Journal of Endocrinology · 359 citations
Carney complex (CNC) is a rare autosomal dominant syndrome, characterized by pigmented lesions of the skin and mucosa, cardiac, cutaneous and other myxomas and multiple endocrine tumors. The diseas...
The 2015 WHO Classification of Tumors of the Heart and Pericardium
Allen Burke, Fabio Tavora · 2015 · Journal of Thoracic Oncology · 259 citations
Minireview: PRKAR1A: Normal and Abnormal Functions
Ioannis Bossis, Constantine A. Stratakis · 2004 · Endocrinology · 199 citations
Abstract The type 1α regulatory subunit (RIα) of cAMP-dependent protein kinase (PKA) (coded by the PRKAR1A gene) is the main component of type I PKA, which regulates most of the serine-threonine ki...
Cardiac Tumors: Diagnosis, Prognosis, and Treatment
Rossana Bussani, Matteo Castrichini, Luca Restivo et al. · 2020 · Current Cardiology Reports · 180 citations
Abstract Purpose of Review Cardiac masses frequently present significant diagnostic and therapeutic clinical challenges and encompass a broad set of lesions that can be either neoplastic or non-neo...
Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update
Anélia Horvath, Jérôme Bertherat, Lionel Groussin et al. · 2010 · Human Mutation · 172 citations
PRKAR1A encodes the regulatory subunit type 1-alpha (RIalpha) of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA). Inactivating PRKAR1A mutations are known to be responsible...
Reading Guide
Foundational Papers
Start with Kirschner et al. (2000) for mutation discovery (1130 citations), then Stratakis et al. (2001) for diagnostics (771 citations), and Bossis and Stratakis (2004) for PKA functions.
Recent Advances
Correa et al. (2015) updates clinical features (359 citations); Horvath et al. (2010) details mutations (172 citations).
Core Methods
Genetic sequencing, echocardiography for myxomas, mouse modeling of PKA disruption (Kirschner et al., 2005). PRKAR1A Sanger sequencing and deletion PCR (Horvath et al., 2010).
How PapersFlow Helps You Research PRKAR1A Mutations in Carney Complex
Discover & Search
Research Agent uses searchPapers and citationGraph to map PRKAR1A literature from Kirschner et al. (2000, 1130 citations) as the hub, revealing Stratakis et al. (2001) clusters. exaSearch uncovers rare deletion variants; findSimilarPapers extends to PPNAD overlaps like Groussin et al. (2002).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation data from Horvath et al. (2010), then runPythonAnalysis for variant frequency stats via pandas. verifyResponse with CoVe and GRADE grading confirms phenotype correlations against Stratakis et al. (2001), flagging inconsistencies statistically.
Synthesize & Write
Synthesis Agent detects gaps in recurrence therapies post-Correa et al. (2015), flags PKA contradictions across Bossis and Stratakis (2004). Writing Agent uses latexEditText, latexSyncCitations for PRKAR1A review drafts, latexCompile for publication-ready PDFs, exportMermaid for signaling diagrams.
Use Cases
"Analyze PRKAR1A mutation frequencies in Carney complex cardiac myxomas from 2000-2020 papers."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Horvath 2010, Kirschner 2000) → runPythonAnalysis (pandas mutation tally, matplotlib plots) → CSV export of variant stats.
"Draft LaTeX review on Carney complex diagnostic criteria with citations."
Research Agent → citationGraph (Stratakis 2001 hub) → Synthesis → gap detection → Writing Agent → latexEditText (criteria section) → latexSyncCitations → latexCompile → PDF with myxoma figures.
"Find GitHub repos modeling PRKAR1A PKA signaling from mouse studies."
Research Agent → paperExtractUrls (Kirschner 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (sandbox simulation of cAMP tissues).
Automated Workflows
Deep Research workflow scans 50+ PRKAR1A papers via searchPapers → citationGraph, generating structured reports on mutation-phenotype links from Kirschner et al. (2000). DeepScan applies 7-step CoVe analysis to verify myxoma recurrence data in Correa et al. (2015), with GRADE checkpoints. Theorizer synthesizes PKA disruption theories from Bossis and Stratakis (2004) mouse validations.
Frequently Asked Questions
What defines PRKAR1A mutations in Carney complex?
Inactivating mutations in PRKAR1A, encoding PKA RIα, disrupt cAMP signaling, causing cardiac myxomas and endocrine tumors (Kirschner et al., 2000).
What are key diagnostic methods?
Genetic sequencing detects PRKAR1A variants; echocardiography screens cardiac myxomas. Stratakis et al. (2001) established criteria including pigmented lesions and family history.
What are seminal papers?
Kirschner et al. (2000, 1130 citations) identified mutations; Stratakis et al. (2001, 771 citations) defined features; Correa et al. (2015, 359 citations) updated clinically.
What open problems exist?
Therapies targeting recurrent myxomas and full mutation spectrum effects remain unsolved. Genotype-phenotype variability challenges screening (Horvath et al., 2010; Correa et al., 2015).
Research Cardiac tumors and thrombi with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PRKAR1A Mutations in Carney Complex with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cardiac tumors and thrombi Research Guide